{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Establish a maximum tolerated dose (MTD) of romidepsin in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (phase I)","groups":[{"description":"Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined","id":"OG000","title":"ALL Patients"}],"populationDescription":"MTD not established as study terminated while only 2 subjects enrolled. Only romidepsin dose tested was 9mg/mg2","reportingStatus":"POSTED","timeFrame":"During the duration of the study (from first to last dose of study drug, on average ten 28-day cycles)","title":"Maximum Tolerated Dose (MTD) of Romidepsin in Combination With Pomalidomide and Dexamethasone","type":"PRIMARY"}